$62.22
1.39% today
NYSE, Nov 13, 07:20 pm CET
ISIN
US03770N1019
Symbol
APGE

Apogee Therapeutics Stock price

$63.10
+9.13 16.92% 1M
+23.52 59.42% 6M
+17.80 39.29% YTD
+5.75 10.03% 1Y
+41.87 197.22% 3Y
+41.87 197.22% 5Y
+41.87 197.22% 10Y
+41.87 197.22% 20Y
NYSE, Closing price Wed, Nov 12 2025
+0.15 0.24%
ISIN
US03770N1019
Symbol
APGE
Industry

Key metrics

Basic
Market capitalization
$4.3b
Enterprise Value
$3.8b
Net debt
positive
Cash
$505.4m
Shares outstanding
58.6m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
7.0
Financial Health
Equity Ratio
95.1%
Return on Equity
-25.4%
ROCE
-43.3%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-270.1m | $-292.7m
EBIT
$-270.8m | $-300.3m
Net Income
$-237.7m | $-268.0m
Free Cash Flow
$-226.6m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-88.0% | -35.1%
EBIT
-88.4% | -38.5%
Net Income
-100.6% | -47.1%
Free Cash Flow
-103.9%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-4.1
FCF per Share
$-3.9
Short interest
21.7%
Employees
196
Rev per Employee
$0.0
Show more

Is Apogee Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,031 stocks worldwide.

Apogee Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

17 Analysts have issued a Apogee Therapeutics forecast:

16x Buy
94%
1x Hold
6%

Analyst Opinions

17 Analysts have issued a Apogee Therapeutics forecast:

Buy
94%
Hold
6%

Financial data from Apogee Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 63 63
75% 75%
-
- Research and Development Expense 208 208
93% 93%
-
-270 -270
88% 88%
-
- Depreciation and Amortization 0.73 0.73
943% 943%
-
EBIT (Operating Income) EBIT -271 -271
88% 88%
-
Net Profit -238 -238
101% 101%
-

In millions USD.

Don't miss a Thing! We will send you all news about Apogee Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Apogee Therapeutics Stock News

Neutral
GlobeNewsWire
3 days ago
Pipeline programs continue to advance, with four clinical data readouts anticipated in 2026; APG777 trial readout timelines accelerated, with Phase 1b in asthma and APEX 52-week Part A data in AD anticipated in Q1 2026, APEX 16-week Part B data in AD in Q2 2026, and APG279 Phase 1b head-to-head readout against DUPIXENT in AD in 2H 2026
Neutral
GlobeNewsWire
3 days ago
Interim Phase 1 results for APG333 exceeded trial objectives, demonstrated a half-life of approximately 55 days, and suppressed key biomarkers for 6 months following a single dose, supporting potential 3- and 6- month dosing
Neutral
GlobeNewsWire
10 days ago
SAN FRANCISCO and BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), today announced that members of management will participate at the following investor conferences. Guggenheim 2 nd Annual Healthcare Innovation Conference  Date: Tuesday, November 11, 2025Fireside Chat Time: 1:30 p.m.
More Apogee Therapeutics News

Company Profile

Apogee Therapeutics, Inc. operates as a biotechnology company. It offers treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications. The company was founded in February 2022 and is headquartered in Waltham, MA.

Head office United States
CEO Michael Henderson
Employees 196
Founded 2022
Website apogeetherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today